Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 323
Filtrar
1.
JAMA ; 329(18): 1545-1546, 2023 05 09.
Artigo em Inglês | MEDLINE | ID: mdl-37052901

RESUMO

This Viewpoint details how and why improved oversight of private equity acquisition of physician practices and hospitals is needed to mitigate the effects on health care costs, clinicians' jobs, and patients' access to care.


Assuntos
Atenção à Saúde , Equidade em Saúde , Política de Saúde , Setor Privado , Atenção à Saúde/legislação & jurisprudência , Atenção à Saúde/organização & administração , Equidade em Saúde/legislação & jurisprudência , Política de Saúde/legislação & jurisprudência , Setor Privado/legislação & jurisprudência
3.
PLoS One ; 16(12): e0261342, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34914798

RESUMO

In 2016, China implemented an environmental protection tax (EPTL2016) to promote the transformation and upgrading of heavily polluting industries through tax leverage. Using panel data of China's listed companies, this study assesses the treatment effects of the EPTL2016 on the transformation and upgrading of heavily polluting firms by incorporating the intermediary role of the financial market. The empirical findings show that the EPTL2016 significantly reduced the innovation investment and productivity of heavily polluting firms but had no significant effect on fixed-asset investment. Additionally, EPTL2016 reduced the supply of bank loans to heavily polluting firms and increased the value of growth options for private enterprises and the efficiency of the supply of long-term loans to heavily polluting firms. Although the environmental policy of EPTL2016 benefits the transformation and upgrading of heavily polluting industries in many aspects, it generally hinders the industrial upgrading because of the reduction of bank loans.


Assuntos
Política Ambiental/economia , Poluição Ambiental/prevenção & controle , Impostos/economia , China , Comércio/legislação & jurisprudência , Conservação dos Recursos Naturais/economia , Conservação dos Recursos Naturais/métodos , Política Ambiental/tendências , Poluentes Ambientais/economia , Poluição Ambiental/economia , Metalurgia/legislação & jurisprudência , Setor Privado/legislação & jurisprudência , Impostos/tendências
6.
S Afr Med J ; 111(7): 661-667, 2021 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-34382550

RESUMO

BACKGROUND:  The viability of obstetric practice in the private sector has been threatened as a result of steep increases in professional indemnity fees over the past 10 years. Despite this, empirical research investigating key aetiological factors to target risk management interventions has been lacking. OBJECTIVES: To explore private practice medicolegal data linked to obstetricians and gynaecologists (O&Gs) to identify factors in clinical practice associated with claims, for the purposes of guiding future research and risk management solutions. METHODS:  This was a retrospective, observational study of private sector O&Gs' medicolegal case histories. All incidents declared to a prominent local professional indemnity insurer were categorised in terms of medicolegal case type, as well as clinical parameters. To allow for risk-adjusted calculations of case incidence, year of entry into private practice was estimated for all practitioners. RESULTS:  Steep increases in medicolegal investigations and demands were demonstrated for both obstetrics- and gynaecology-related cases from about 2003 to 2012. Whereas the total numbers of claims, regulatory complaints and requests for records were similar for obstetrics and gynaecology in recent years (accounting for 52% v. 48% of known cases, respectively), a significantly greater percentage of demands and paid settlements related to gynaecology rather than obstetrics (58% and 76% v. 42% and 24% of cases, respectively). In obstetrics, about half of all cases on record with a paid settlement were in the context of severe neonatal birth-related neurological injury (n=9). For gynaecology, procedure-related complications accounted for 92% of settlements, of which at least 41% were for intraoperative injuries to internal organs and vessels. Laparoscopic procedures were most frequently associated with such intraoperative injuries, followed by vaginal and abdominal hysterectomies/oophorectomies and caesarean sections. For O&Gs in private practice for >2 years, 50/458 (11%) accounted for 138/228 (61%) of demands over a 10-year period. CONCLUSIONS:  The higher number of gynaecological demands and settlements in comparison with obstetric cases was unexpected and is contrary to international experiences and public sector findings, calling for more research to identify reasons for this finding. Other than further exploring surgical outcomes in private sector gynaecological patients, aspects of surgical training and accreditation standards in gynaecology may need review. Regarding birth-related injuries, the contribution of system failures needs quantification and further interrogation. The high contribution towards the medicolegal burden by a small group of practitioners suggests a need for doctor-focused interventions, including strengthening of peer review and regulatory oversight.


Assuntos
Ginecologia/legislação & jurisprudência , Imperícia/estatística & dados numéricos , Obstetrícia/legislação & jurisprudência , Adulto , Idoso , Parto Obstétrico/efeitos adversos , Parto Obstétrico/legislação & jurisprudência , Feminino , Humanos , Recém-Nascido , Doenças do Recém-Nascido/etiologia , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Obstétricos/efeitos adversos , Procedimentos Cirúrgicos Obstétricos/legislação & jurisprudência , Setor Privado/legislação & jurisprudência , Setor Privado/estatística & dados numéricos , Estudos Retrospectivos , África do Sul
8.
Cochrane Database Syst Rev ; 2: CD011512, 2021 02 22.
Artigo em Inglês | MEDLINE | ID: mdl-33617665

RESUMO

BACKGROUND: The strain on public resources to meet the healthcare needs of populations through publicly-provided health insurance programmes is increasing and many governments turn to private health insurance (PHI) to ease the pressure on government budgets. With the goal of improving access to basic health care for citizens through PHI programmes, several high-income countries have developed strong regulations for PHI schemes. Low- and middle-income countries have the opportunity to learn from this experience to optimise PHI. If poorly regulated, PHI can hardly achieve an adequate quantity or quality of population coverage, as can be seen in the USA where a third of adults younger than 65 years of age have no insurance, sporadic coverage or coverage that exposes them to high out-of-pocket healthcare costs. OBJECTIVES: To assess the effects of policies that regulate private health insurance on utilisation, quality, and cost of health care provided. SEARCH METHODS: In November 2019 we searched CENTRAL; MEDLINE; Embase; Sociological Abstracts and Social Services Abstracts; ICTRP; ClinicalTrials.gov; and Web of Science Core Collection for papers that have cited the included studies. This complemented the search conducted in February 2017 in IBSS; EconLit; and Global Health. We also searched selected grey literature databases and web-sites.  SELECTION CRITERIA: Randomised trials, non-randomised trials, interrupted time series (ITS) studies, and controlled before-after (CBA) studies conducted in any population or setting that assessed one or more of the following interventions that governments use to regulate private health insurance: legislation and licensing, monitoring, auditing, and intelligence. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed study eligibility, extracted data, and assessed risk of bias and certainty of the evidence resolving discrepancies by consensus. We planned to summarise the results (using random-effects or fixed-effect meta-analysis) to produce an overall summary if an average intervention effect across studies was considered meaningful, and we would have discussed the implications of any differences in intervention effects across studies. However, due to the nature of the data obtained, we have provided a narrative synthesis of the findings. MAIN RESULTS: We included seven CBA studies, conducted in the USA, and that directly assessed state laws on cancer screening. Only for-profit PHI schemes were addressed in the included studies and no study addressed other types of PHI (community and not for-profit). The seven studies were assessed as having 'unclear risk' of bias. All seven studies reported on utilisation of healthcare services, and one study reported on costs. None of the included studies reported on quality of health care and patient health outcomes. We assessed the certainty of evidence for patient health outcomes, and utilisation and costs of healthcare services as very low. Therefore, we are uncertain of the effects of government mandates on for-profit PHI schemes. AUTHORS' CONCLUSIONS: Our review suggests that, from currently available evidence, it is uncertain whether policies that regulate private health insurance have an effect on utilisation of healthcare services, costs, quality of care, or patient health outcomes. The findings come from studies conducted in the USA and might therefore not be applicable to other countries; since the regulatory environment could be different. Studies are required in countries at different income levels because the effects of government regulation of PHI are likely to differ across these income and health system settings. Further studies should assess the different types of regulation (including regulation and licensing, monitoring, auditing, and intelligence). While regulatory research on PHI remains relatively scanty, future research can draw on the rich body of research on the regulation of other health financing interventions such as user fees and results-based provider payments.


Assuntos
Regulamentação Governamental , Seguro Saúde/legislação & jurisprudência , Setor Privado/legislação & jurisprudência , Governo Estadual , Viés , Neoplasias Colorretais/diagnóstico , Estudos Controlados Antes e Depois/estatística & dados numéricos , Feminino , Custos de Cuidados de Saúde , Necessidades e Demandas de Serviços de Saúde/legislação & jurisprudência , Humanos , Seguro Saúde/economia , Masculino , Setor Privado/economia , Neoplasias da Próstata/diagnóstico , Estados Unidos , Neoplasias do Colo do Útero/diagnóstico
9.
Am J Clin Nutr ; 111(6): 1278-1285, 2020 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-32412583

RESUMO

BACKGROUND: Many lower-income communities in the United States lack a full-line grocery store. There is evidence that the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) increases the availability of healthy foods in stores. One national discount variety store chain (DVS) that is often located in low-income neighborhoods became an authorized WIC vendor in 8 pilot stores. OBJECTIVES: The objective of this study was to evaluate how implementing WIC in DVS pilot stores affected sales of healthy, WIC-eligible foods. METHODS: We used DVS sales data and difference-in-differences regression to evaluate how WIC authorization affected sales of WIC-eligible foods in 8 DVS pilot stores, compared with 8 matched comparison stores. RESULTS: DVS added 18 new WIC-approved foods to become an authorized vendor. Results indicate that becoming a WIC vendor significantly increased sales of healthy, WIC-eligible foods that DVS carried before authorization. WIC implementation in DVS led to a 31-unit increase in sales of the original WIC foods per week on average (P < 0.01). Lower socioeconomic status, assessed using a summary measure, is associated with increased sales of WIC foods. Yet sales of non-WIC eligible foods (e.g., salty snack foods, candy bars, soda, and processed meats) were not affected by WIC authorization. CONCLUSIONS: Encouraging DVS stores to become WIC-authorized vendors has the potential to modestly increase DVS sales and the availability of healthy foods in low-income neighborhoods. If WIC authorization is financially viable for small-format variety stores, encouraging similar small-format variety stores to become WIC-authorized has the potential to improve food access.


Assuntos
Assistência Alimentar/economia , Abastecimento de Alimentos/economia , Alimentos/economia , Setor Privado/economia , Comércio/legislação & jurisprudência , Feminino , Assistência Alimentar/legislação & jurisprudência , Abastecimento de Alimentos/legislação & jurisprudência , Promoção da Saúde/economia , Humanos , Masculino , Pobreza , Autorização Prévia , Setor Privado/legislação & jurisprudência , Estados Unidos
10.
Rev Saude Publica ; 54: 42, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32321058

RESUMO

OBJECTIVE: To describe students protected by laws and exposed to soft drinks sales and assess whether forbidding laws are associated with lower availability of these beverages. METHODS: We identified laws forbidding non-government administered cafeterias or sales of soft drinks in schools in the 27 Brazilian state capitals. Data on soft drinks sales were obtained from Pesquisa Nacional de Saúde do Escolar 2015 (PeNSE - National Survey of School Health 2015), for a representative sample of 9th graders from public and private schools. Students were attributed with the status of their school regarding the law and sale of soft drinks. Co-variables were school status (public or private), school size, geographic regions, mother's educational level, score of goods and services. We performed multivariate analyses using Poisson regression. RESULTS: The total of 23 laws forbidding sales of soft drinks covered 63.0% of capitals, comprising 56.9% of students. Law coverage was higher among students from more developed regions (67.6%) and in public schools (60.6%), compared with those from less developed regions (38.0%) and private schools (45.8%). Soft drinks were available for 33.9% of students. Students attending public schools in less developed regions had the lowest availability of soft drinks, regardless of law coverage (14.8%; 12.0%); while students attending private schools in these regions had a high availability, regardless of law coverage (82.1%; 73.4%). Restrictive laws were associated with lower sales of soft drinks in more developed regions, and restrictions had a greater association with the availability of soft drinks in public schools (PR = 0.25; 95%CI = 0.15-0.41), compared with private schools (PR = 0.48; 95%CI = 0.35-0.66). CONCLUSION: Laws restricting soft drinks in schools were associated with fewer sales in more developed regions. Private schools were less compliant with the law than public schools. A broadly enforced national law could reduce the availability of soft drinks in schools.


Assuntos
Bebidas Gaseificadas/legislação & jurisprudência , Comércio/legislação & jurisprudência , Instituições Acadêmicas/legislação & jurisprudência , Brasil , Fidelidade a Diretrizes/estatística & dados numéricos , Humanos , Setor Privado/legislação & jurisprudência , Setor Público/legislação & jurisprudência , Instituições Acadêmicas/estatística & dados numéricos , Estudantes/estatística & dados numéricos , Inquéritos e Questionários
11.
Sci Eng Ethics ; 26(1): 1-25, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31123979

RESUMO

Stem cell technology is an emerging science field; it is the unique regenerative ability of the pluripotent stem cell which scientists hope would be effective in treating various medical conditions. While it has gained significant advances in research, it is a sensitive subject involving human embryo destruction and human experimentation, which compel governments worldwide to ensure that the related procedures and experiments are conducted ethically. Based on face-to-face interviews with selected Malaysian ethicists, scientists and policymakers, the objectives and effectiveness of the current Guideline for Stem Cell Research and Therapy (2009) are examined. The study's findings show that the guideline is rather ineffective in ensuring good ethical governance of the technology. A greater extent of unethical conduct is likely present in the private medical clinics or laboratories offering stem cell therapies compared with the public medical institutions providing similar services, as the latter are closely monitored by the governmental agencies enforcing the relevant policies and laws. To address concerns over malpractices or unethical conduct, this paper recommends a comprehensive revision of the current stem cell guideline so that adequate provisions exist to regulate the explicit practices of the private and public stem cell sectors, including false advertising and accountability. The newly revised Malaysian stem cell guideline will align with the Guidelines for Stem Cell Research and Clinical Translation (2016) of the International Society for Stem Cell Research (ISSCR) containing secular but universal moral rules. However, a regulatory policy formulated to govern the technology remains the main thrust of empowering the guideline for compliance among the stakeholders.


Assuntos
Guias como Assunto , Políticas , Pesquisa com Células-Tronco/ética , Pesquisa com Células-Tronco/legislação & jurisprudência , Tecnologia Biomédica/ética , Tecnologia Biomédica/legislação & jurisprudência , Humanos , Malásia , Turismo Médico , Setor Privado/ética , Setor Privado/legislação & jurisprudência , Má Conduta Profissional , Setor Público/ética , Setor Público/legislação & jurisprudência , Religião e Ciência
12.
Rev. saúde pública (Online) ; 54: 42, 2020. tab, graf
Artigo em Inglês | LILACS, BBO - Odontologia | ID: biblio-1101857

RESUMO

ABSTRACT OBJECTIVE To describe students protected by laws and exposed to soft drinks sales and assess whether forbidding laws are associated with lower availability of these beverages. METHODS We identified laws forbidding non-government administered cafeterias or sales of soft drinks in schools in the 27 Brazilian state capitals. Data on soft drinks sales were obtained from Pesquisa Nacional de Saúde do Escolar 2015 (PeNSE - National Survey of School Health 2015), for a representative sample of 9th graders from public and private schools. Students were attributed with the status of their school regarding the law and sale of soft drinks. Co-variables were school status (public or private), school size, geographic regions, mother's educational level, score of goods and services. We performed multivariate analyses using Poisson regression. RESULTS The total of 23 laws forbidding sales of soft drinks covered 63.0% of capitals, comprising 56.9% of students. Law coverage was higher among students from more developed regions (67.6%) and in public schools (60.6%), compared with those from less developed regions (38.0%) and private schools (45.8%). Soft drinks were available for 33.9% of students. Students attending public schools in less developed regions had the lowest availability of soft drinks, regardless of law coverage (14.8%; 12.0%); while students attending private schools in these regions had a high availability, regardless of law coverage (82.1%; 73.4%). Restrictive laws were associated with lower sales of soft drinks in more developed regions, and restrictions had a greater association with the availability of soft drinks in public schools (PR = 0.25; 95%CI = 0.15-0.41), compared with private schools (PR = 0.48; 95%CI = 0.35-0.66). CONCLUSION Laws restricting soft drinks in schools were associated with fewer sales in more developed regions. Private schools were less compliant with the law than public schools. A broadly enforced national law could reduce the availability of soft drinks in schools.


Assuntos
Humanos , Instituições Acadêmicas/legislação & jurisprudência , Bebidas Gaseificadas , Comércio/legislação & jurisprudência , Instituições Acadêmicas/estatística & dados numéricos , Estudantes/estatística & dados numéricos , Brasil , Inquéritos e Questionários , Setor Público/legislação & jurisprudência , Setor Privado/legislação & jurisprudência , Fidelidade a Diretrizes/estatística & dados numéricos
13.
Indian J Med Ethics ; 4(2): 120-122, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31271362

RESUMO

The Government of India has passed a notification making the non-reporting of tuberculosis (TB) by a clinical establishment a punishable offence. This article examines this move from an ethical standpoint. One of the main ethical concerns relates to the violation of patient confidentiality that may result from this. Also as regards improvement in patient care, there appears to be a poor cost-benefit ratio in terms of the actionable data obtained by this There may be possible adverse consequences by a limiting of access to care due to penalising of non-reporting. In terms of the bigger picture, the notification may lead to an increased tension between the private sector and Government. Moreover, it is the position of the authors that such a step distracts attention from the more important issues that plague TB care in India today.


Assuntos
Confidencialidade/ética , Revelação/ética , Notificação de Doenças/legislação & jurisprudência , Política de Saúde/legislação & jurisprudência , Notificação de Abuso/ética , Tuberculose/epidemiologia , Humanos , Índia/epidemiologia , Setor Privado/legislação & jurisprudência , Saúde Pública/legislação & jurisprudência
14.
BJS Open ; 3(3): 314-316, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-31183447

RESUMO

Background: Laparoscopic adjustable gastric banding (LAGB) remains a commonly performed procedure for morbid obesity. Concerns regarding its long-term consequences include high rates of band removal from complications and failure to lose weight. Many private practices continue to perform LAGB but, owing to short follow-up periods, the burden of surgical complications falls upon National Health Service (NHS) bariatric units. This study aimed to review the NHS treatment of patients for complications related to privately performed LAGB. Methods: All surgical complications following bariatric surgery referred to the Welsh Institute of Metabolic and Obesity Surgery (WIMOS) between September 2010 and September 2014 were reviewed. Type of complication, procedures performed, and number of outpatient attendances and inpatient stays were recorded. Costs of treatment were estimated using standard tariffs. Results: A total of 78 patients presented with complications after privately performed bariatric surgery. Sixty had undergone LAGB; the remainder had had other bariatric procedures. Median age was 45 (range 22-78) years, and 65 (83 per cent) were women. Urgent band deflation was undertaken in 53 patients. Band removal surgery was required in 32 patients; one patient needed a subtotal gastrectomy. There was a total of 123 outpatient/ward attendances and 340 days of inpatient care, including 10 days of intensive care. The estimated total cost to the NHS of managing these patients was €337 400 (€84 350 per annum). Conclusion: The cost burden to the NHS of managing the complications of bariatric surgery performed in the private sector is considerable. Although it is imperative that such complications be managed in well equipped specialist units, private surgery providers should have better follow-up plans and/or contractual agreements with the NHS.


Assuntos
Laparoscopia/economia , Laparoscopia/instrumentação , Programas Nacionais de Saúde/economia , Obesidade Mórbida/cirurgia , Reoperação/economia , Adulto , Idoso , Enfermagem de Cuidados Críticos/estatística & dados numéricos , Feminino , Gastrectomia/métodos , Custos Hospitalares/tendências , Humanos , Laparoscopia/efeitos adversos , Masculino , Pessoa de Meia-Idade , Programas Nacionais de Saúde/estatística & dados numéricos , Obesidade Mórbida/epidemiologia , Complicações Pós-Operatórias/economia , Setor Privado/legislação & jurisprudência , Setor Privado/estatística & dados numéricos , Reoperação/estatística & dados numéricos , Reino Unido/epidemiologia
15.
J Appl Psychol ; 104(9): 1181-1194, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30829511

RESUMO

This article advances the understanding of when and how formal status of small-scale entrepreneurs can contribute to higher growth in comparison to their informal counterparts. Our integrative framework suggests that both formal status and personal initiative (PI) behavior have a common pathway to predict firm growth. More importantly, formal firms improve their growth perspectives only if the entrepreneurs show a high degree of PI. The integrative framework was tested using longitudinal data with 2 measurement points with a total of 190 formal and informal entrepreneurs in the Sub-Saharan African country of Zimbabwe. Results show that both formal status and PI have indirect effects on firm growth through available resources. Further, PI has a dual-path moderating effect on the indirect effect of formal status to firm growth such that the indirect effect of formal status on firm growth via available resources is strongest when entrepreneurs have high PI, but there is no indirect effect when PI is low. Our research shows the importance of considering the interplay of institutional and psychological factors for explaining firm growth in developing countries. (PsycINFO Database Record (c) 2019 APA, all rights reserved).


Assuntos
Comércio , Emprego , Motivação , Setor Privado , Adulto , Comércio/legislação & jurisprudência , Países em Desenvolvimento , Emprego/legislação & jurisprudência , Humanos , Setor Informal , Estudos Longitudinais , Masculino , Setor Privado/legislação & jurisprudência , Zimbábue
16.
Aust Health Rev ; 43(5): 572-577, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30857589

RESUMO

Objective This study explored the current activities of a sample of Australian private health insurance (PHI) funds to support the care of people living with chronic conditions, following changes to PHI legislation in 2007 permitting funds to cover a broader range of chronic disease management (CDM) services. Methods A qualitative research design was used to gather perspectives from PHI sector representatives via semistructured interviews with eight participants. The interview data were analysed systematically using the framework analysis method. Results Three main types of activities were most commonly identified: (1) healthcare navigation; (2) structured disease management and health coaching programs; and (3) care coordination services. These activities were primarily conducted via telephone by a combination of in-house and third-party health professionals. PHI funds seem to be taking a pragmatic approach to the type of CDM activities currently offered, guided by available data and identified member need. Activities are focused on people with diagnosed chronic conditions exiting hospital, rather than the broader population at-risk of developing a chronic condition. Conclusions Despite legislation permitting PHI funds to pay benefits for CDM services being in place for more than 10 years, insurers are still in an early stage of implementation and evaluation of CDM activities. Primarily due to the regulated scope of PHI coverage in Australia, participants reported several challenges in providing CDM services, including identifying target groups, evaluating service outcomes and collaborating with other healthcare providers. The effectiveness of the approach of PHI funds to CDM in terms of the groups targeted and outcomes of services provided still needs to be established because evidence suggests that population-level interventions that target a larger number of people with lower levels of risks are likely to have greater benefit than targeting a small number of high-risk cases. What is known about the topic? Since 2007, PHI funds in Australia have been able to pay benefits for a range of out-of-hospital services, focused on CDM. Although a small number of program evaluations has been published, there is little information on the scope of activities and the factors influencing the design and implementation of CDM programs. What does this paper add? This paper presents the findings of a qualitative study reporting on the CDM activities offered by a sample of PHI funds, their approach to delivery and the challenges and constraints in designing and implementing CDM activities, given the PHI sector's role as a supplementary health insurer in the Australian health system. What are the implications for practitioners? Current CDM activities offered by insurers focus on health navigation advice, structured, time-limited CDM programs and care coordination services for people following a hospital admission. There is currently little integration of these programs with the care provided by other health professionals for a person accessing these services. Although the role of insurers is currently small, the movement of insurers into service provision raises considerations for managing potential conflicts in having a dual role as an insurer and provider, including the effectiveness and value of services offered, and how these programs complement other types of health care being received.


Assuntos
Doença Crônica/terapia , Gerenciamento Clínico , Seguradoras , Seguro Saúde , Setor Privado , Austrália , Humanos , Seguradoras/legislação & jurisprudência , Seguro Saúde/legislação & jurisprudência , Entrevistas como Assunto , Setor Privado/legislação & jurisprudência , Pesquisa Qualitativa
17.
Int J Health Serv ; 49(2): 204-211, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30638431

RESUMO

Election to the parliament was held in Sweden on 9 September 2018. None of the traditional political blocks obtained a majority of the vote. The nationalist Sweden Democrats party increased their share of the vote from 13% in 2014 elections to 17% of the vote in 2018. As no traditional political block wants to collaborate with the Sweden Democrats, no new government has yet been formed, more than 2 months after the election. Health care was a prominent issue in the elections. Health care in Sweden is universal and tax-funded, with a strong emphasis on equity. However, recent reforms have emphasized market-orientation and privatization in order to increase access to care, and may not contribute to equity. In spite of a majority of the population being opposed to profits being made on publicly funded services, privatization of health and social care has increased in the last decades. The background to this is described. Health is improving in Sweden, but inequalities remain and increase. The Swedish Public Health Policy from 2003 has been revised in 2018, on the basis of a national review of inequalities in health. The revised policy further emphasizes reducing inequalities in health.


Assuntos
Atenção à Saúde/legislação & jurisprudência , Política , Atenção à Saúde/organização & administração , Política de Saúde/legislação & jurisprudência , Nível de Saúde , Humanos , Setor Privado/legislação & jurisprudência , Suécia/epidemiologia
18.
Eur J Health Econ ; 20(4): 597-610, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30564917

RESUMO

This paper presents the first evaluation of the French Disabled Workers Act of 1987, which aimed to promote the employment of disabled people in the private sector. We use a panel data set, which includes both the health and the labour market histories of workers. We account both for unobserved heterogeneity and for the change in the disabled population over time. We find that the law had a negative impact on the employment of disabled workers in the private sector. This counterproductive effect likely comes from the possibility to pay a fine instead of hiring disabled workers.


Assuntos
Pessoas com Deficiência/legislação & jurisprudência , Emprego/legislação & jurisprudência , Adulto , Pessoas com Deficiência/estatística & dados numéricos , Escolaridade , Emprego/estatística & dados numéricos , Feminino , França , Humanos , Masculino , Pessoa de Meia-Idade , Setor Privado/legislação & jurisprudência , Setor Privado/estatística & dados numéricos , Política Pública/legislação & jurisprudência , Fatores Sexuais
19.
Curr Obes Rep ; 7(3): 211-219, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30022469

RESUMO

PURPOSE OF REVIEW: There is a critical need for corporations to be part of the solutions to major societal issues, such as obesity. Investment decisions can have a substantial impact on both corporate practices and population health. This paper aimed to explore potential mechanisms for incorporating obesity and related nutrition considerations into responsible investment (RI) approaches. RECENT FINDINGS: We found that there are a number of available strategies for the investment community to incorporate obesity considerations into their decisions. However, despite some recent efforts to improve company disclosure in the area and the emergence of new tools for assessing food company nutrition policies, the inclusion of obesity and related nutrition considerations as part of RI is currently extremely limited. There appears to be substantial scope to apply approaches already in widespread use for other RI considerations to the area of obesity. Ways in which to apply measurement frameworks across different markets and sectors need to be explored.


Assuntos
Dieta Saudável , Dieta/efeitos adversos , Indústria Alimentícia , Promoção da Saúde/métodos , Investimentos em Saúde , Estado Nutricional , Obesidade/prevenção & controle , Setor Privado , Indústria Alimentícia/legislação & jurisprudência , Saúde Global , Política de Saúde , Promoção da Saúde/legislação & jurisprudência , Humanos , Investimentos em Saúde/legislação & jurisprudência , Valor Nutritivo , Obesidade/epidemiologia , Obesidade/fisiopatologia , Formulação de Políticas , Setor Privado/legislação & jurisprudência , Responsabilidade Social , Nações Unidas
20.
Circ Cardiovasc Qual Outcomes ; 11(1): e003939, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29326146

RESUMO

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an innovative treatment option for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require further lowering of low-density lipoprotein cholesterol. However, the high costs of these agents have spurred payers to implement utilization management policies to ensure appropriate use. We examined prior authorization (PA) requirements for PCSK9is across private and public US payers. METHODS AND RESULTS: We conducted an analysis of 2016 formulary coverage and PA data from a large, proprietary database with information on policies governing >95% of Americans with prescription drug coverage (275.3 million lives) within 3872 plans across the 4 major insurance segments (commercial, health insurance exchange, Medicare, and Medicaid). The key measures included administrative PA criteria (prescriber specialty, number of criteria in PA policy or number of fields on PA form, requirements for medical record submission, reauthorization requirements) and clinical/diagnostic PA criteria (approved conditions, required laboratories or other tests, required concomitant therapy, step therapy requirements, continuation criteria) for each of 2 Food and Drug Administration-approved PCSK9is. Select measures (eg, number of PA criteria/fields, medical record submission requirements) were obtained for 2 comparator cardiometabolic drugs (ezetimibe and liraglutide). Between 82% and 97% of individuals were enrolled in plans implementing PA for PCSK9is (depending on insurance segment), and one third to two thirds of these enrollees faced PAs restricting PCSK9i prescribing to a specialist. For patients with familial hypercholesterolemia, diagnostic confirmation via genetic testing or meeting minimum clinical scores/criteria was also required. PA requirements were more extensive for PCSK9is as compared with the other cardiometabolic drugs (ie, contained 3×-11× the number of PA criteria or fields on PA forms and more frequently involved the submission of medical records as supporting documentation). CONCLUSIONS: PA requirements for PCSK9is are greater than for selected other drugs within the cardiometabolic disease area, raising concerns about whether payer policies to discourage inappropriate use may also be restricting access to these drugs in patients who need them.


Assuntos
Anticolesterolemiantes/uso terapêutico , Dislipidemias/tratamento farmacológico , Definição da Elegibilidade , Assistência Médica , Inibidores de PCSK9 , Autorização Prévia , Setor Privado , Inibidores de Serino Proteinase/uso terapêutico , Anticolesterolemiantes/economia , Biomarcadores/sangue , LDL-Colesterol/sangue , Bases de Dados Factuais , Custos de Medicamentos , Dislipidemias/sangue , Dislipidemias/diagnóstico , Dislipidemias/economia , Definição da Elegibilidade/economia , Definição da Elegibilidade/legislação & jurisprudência , Humanos , Assistência Médica/economia , Assistência Médica/legislação & jurisprudência , Formulação de Políticas , Autorização Prévia/economia , Autorização Prévia/legislação & jurisprudência , Setor Privado/economia , Setor Privado/legislação & jurisprudência , Pró-Proteína Convertase 9/metabolismo , Inibidores de Serino Proteinase/economia , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...